Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients
Recruiting
N/A
Interventional Study
ACS - Acute Coronary Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 380 (estimated)
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are \- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Between the ages of 18 and 80
* ACS (STEMI or NSTE-ACS)
* Patients to receive standardised drug therapy
* Able and willing to provide informed consent
Exclusion Criteria:
* Any contraindication to colchicine or known intolerance to colchicine
* Has been using colchicine for …
Contacts